Live Long Live Strong

Rejwin™

Eesha™ HERBALS

Rejwin: Driving Novel Formulation to test Tumor Vulnerabilities



apoptosis • angiogenesis • biotechnology • cancer biology • pharmacology • reproduction

MBL MOLECULAR BIO LABS Inspired by Nature INDIA

IN COLLABORATION WITH

Dr. B.T Prabhakar, M.Sc, Ph. D.
Professor, Molecular Biomedicine Laboratory,
Department of Biotechnology,
Sahyadri Science College, Kuvempu University,
Shivamogga - 577203,

INTRODUCTION



Valyou Products Private Limited is an **ISO, FSSAI, and GMP-certified company** established in **2009** by **Mrs. Ambujakshi A.S. and Dr. Srinivasamuthy A.K.** Located amidst the scenic surroundings of Ramenakoppa in Shivamogga District, Karnataka, the company was founded with a vision to promote health awareness, preventive healthcare, and healthy living through **natural, herbal, and Ayurvedic products.** Since its inception, the organization has been committed to improving the quality of life of individuals by providing scientifically developed wellness solutions that combine the wisdom of **traditional Ayurveda** with modern manufacturing standards.

For more than **14** years, Valyou Products has been engaged in the **research, development, and manufacturing** of high-quality health supplements under its flagship brand, **Amrith Noni.** The company utilizes the medicinal properties of Noni fruit along with carefully selected **Ayurvedic herbs** to formulate products that address a wide range of health concerns and support overall well-being. Its state-of-the-art manufacturing facilities, advanced research laboratories, and stringent quality control systems ensure that every product is manufactured according to the highest standards of **safety, purity, quality, and effectiveness.** The company continuously strives to maintain excellence by adhering to national and international quality benchmarks throughout its production processes.

Valyou Products is recognized as one of the **leading cultivators and manufacturers** of Noni-based products in India. The company follows a unique farm-to-product model that enables complete control over every stage of production. From cultivating Noni fruits and medicinal herbs to processing raw materials and manufacturing finished products, all activities are carried out under a single integrated system. This approach ensures product consistency, superior quality, traceability, sustainability, and enhanced consumer confidence. By maintaining direct involvement in cultivation and production, the company is able to preserve the authenticity and medicinal value of its ingredients while ensuring environmentally responsible practices.

The company also supports farmers through its Noni and Herbs farmers Association, encouraging the cultivation of Noni and medicinal herbs by providing buyback opportunities and technical guidance. Through collaborations with agricultural universities, research institutions, and farming communities, Valyou Products promotes sustainable farming practices and improved cultivation methods. These initiatives help farmers enhance productivity, increase income opportunities, and adopt eco-friendly techniques. More than 60 farmers directly benefit from these programs, while the company has also created employment opportunities through its cultivation, manufacturing, distribution, and marketing activities.





Apart from its business achievements, Valyou Products remains deeply committed to social welfare and community development through the **Valyou Social Welfare Trust.** The trust actively supports educational assistance for underprivileged students, healthcare awareness programs, free diabetic camps, disaster relief initiatives, and various community welfare activities. During the **COVID-19 pandemic**, the organization played an important role in supporting society by providing oxygen-equipped ambulance services, distributing masks and sanitizers, and extending assistance to frontline workers. The company has also contributed to flood relief efforts and offered financial and humanitarian support to individuals and families affected by natural disasters and other emergencies. Through these initiatives, Valyou Products continues to make a meaningful contribution to the welfare and development of communities across the region.



Today, Valyou Products serves customers across Karnataka, Andhra Pradesh, Tamil Nadu, Maharashtra, Gujarat, and several other regions of India, while continuously exploring opportunities in **international markets**. Driven by its commitment to quality, innovation, sustainability, customer satisfaction, and social responsibility, the company continues to expand its reach and strengthen its position in the health and wellness sector. By combining traditional Ayurvedic knowledge with modern scientific approaches, Valyou Products remains dedicated to creating a healthier society and making a meaningful contribution to the well-being of people and communities for generations to come. The company also focuses on building **long-term customer trust** through consistent quality and ethical business practices. It continues to enhance its market presence through customer-focused innovation and excellence.



Live Long Live Strong

CERTIFICATES



INTELLECTUAL PROPERTY INDIA

फ़ॉर्म 8/SL No 044207900

पेटेंट कार्यालय,भारत सरकार
पेटेंट प्रमाण पत्र
(पेटेंट नियमावली का नियम 74)

The Patent Office, Government Of India
Patent Certificate
(Rule 74 of The Patents Rules)

पेटेंट सं. / Patent No. : 591524

आवेदन सं. / Application No. : 202241068184

फाइल करने की तारीख / Date of Filing : 27/11/2022

पेटेंटी / Patentee : 1.AK SRINIVAS MURTHY 2.Ambujakshi AS

प्रमाणित किया जाता है कि पेटेंटी को, उपरोक्त आवेदन में यथाप्रकटित *A METHOD AND COMPOSITION FOR PREPARATION OF HERBAL SOLUTION FOR CANCER TREATMENT* नामक आविष्कार के लिए, पेटेंट अधिनियम, 1970 के उपबंधों के अनुसार आज तारीख नवम्बर 2022 के सत्ताईसवें दिन से बीस वर्ष की अवधि के लिए पेटेंट अनुदत्त किया गया है।

It is hereby certified that a patent has been granted to the patentee for an invention entitled *A METHOD AND COMPOSITION FOR PREPARATION OF HERBAL SOLUTION FOR CANCER TREATMENT* as disclosed in the above mentioned application for the term of 20 years from the 27th day of November 2022 in accordance with the provisions of the Patents Act,1970.

अनुदान की तारीख / Date of Grant : 08/06/2026

पेटेंट नियंत्रक
Controller of Patents

टिप्पणी - इस पेटेंट के नवीकरण के लिए फीस, यदि इसे बनाए रखा जाना है, नवम्बर 2024 के सत्ताईसवें दिन को और उसके पश्चात प्रत्येक वर्ष में उसी दिन देय होगी।

Note. - The fees for renewal of this patent, if it is to be maintained, will fall / has fallen due on 27th day of November 2024 and on the same day in every year thereafter.

RPAD

GOVERNMENT OF KARNATAKA
KARNATAKA STATE DRUG LICENSING AUTHORITY
Ground Floor, Directorate of AYUSH, Dhanwantari Road, Bengaluru-560009
E-mail: ayushdli@gmail.com Tel. No. 080-22371840

No.Ayush/338/DLA1/2024 Date:09-12-2024

LETTER OF RETENTION

Sub:- Retention of GMP Certificate pertaining to License No.AUS-862.

Ref:- Your application dated: 03-10-2024

*****

Considering your application & the enclosures submitted along with it, you are hereby informed that License No. **AUS-862** in Form 25 D and Good Manufacturing Practices Certificate in Form 26 E1 issued to your company for manufacturing of ASU drugs, is valid perpetually subject to the condition of submission of self declaration of adherence to the conditions of license and the provisions of the Drugs and Cosmetics Act and the rules made thereunder, on **16th October** every year.

Further you are required to pay Good Manufacturing certificate retention fee on or before **15-10-2029** failing which you shall be liable to pay certificate retention fee along with a late fee calculated at the rate of two percent of the certificate retention fee for every month or part thereof up to 6 months, and in the event of non-payment of such fee, the certificate shall be deemed to have been cancelled.

The list of approved drugs is enclosed herewith.

09.12.24

Date: 09-12-2024

Drug Licensing Authority
Drug Licensing Authority
Department of AYUSH
Dhanwanthari Road, Bengaluru-560009

To,
M/S Valyou Products Private Limited,
Raminakoppa, Hosahalli Post,
Shivamogga-577202.

Ref No. 3962/AD/78/DLA/2019-20

Office of the Drugs Licensing Authority
Department of AYUSH
Dhanwanthari Roads, Bangalore-560009
Date: 16-10-2019

CERTIFICATE OF GOOD MANUFACTURING PRACTICES (GMP) to

From 26 E-1
(See Rule 155-B)

Certified that manufacturing unit Licensee, namely **M/s Valyou Products Private Limited.** Raminakoppa, Hosahalli Post, Shimoga-577202, *State: Karnataka* License No. **AUS-862** comply with the requirements of **GOOD MANUFACTURING PRACTICES (GMP)** of Ayurveda-Siddha-Unani drugs as laid down in **schedule "T"** of the Drugs and Cosmetics Rules, 1945.

This Certificate is valid for a period of five years from **16-10-2019 to 15-10-2024** and the GMP is valid for the various dosage form or rasoushadhis as follows: Oral Liquid, Taila, Soap.

16.10.19

Date: 16-10-2019
Place: Bangalore

Deputy Drugs Controller and
Licensing Authority for Ayurveda/
Siddha/Unani Drugs.

N.B. Apply for GMP certificate along with manufacturing license renewal before 3 months from the date of its expiry.

CANCER

Cancer is a group of diseases characterized by the uncontrolled growth and abnormal behaviour of cells. Normally, healthy cells grow, divide, repair damage and undergo programmed cell death (apoptosis) when no longer needed. In cancer, genetic and molecular changes disrupt these processes, allowing abnormal cells to multiply uncontrollably.

As these cells accumulate, they may form a tumour. Malignant tumours can invade surrounding tissues and spread to distant organs through the blood or lymphatic system, a process known as metastasis.

Cancer can develop in almost any tissue or organ, and different types vary in their causes, progression and response to treatment. Factors that may contribute to cancer development include:

- **Genetic mutations:** Changes affecting cell growth, DNA repair and programmed cell death.
- **Environmental exposures:** Tobacco, alcohol, certain chemicals, pollutants and radiation.
- **Infections:** Certain viruses and bacteria associated with specific cancers.
- **Chronic inflammation and oxidative stress:** Processes that may contribute to cellular damage.
- **Hormonal and metabolic changes:** Imbalances that may influence cell growth.
- **Lifestyle factors:** Obesity, physical inactivity and dietary habits.
- **Age-related changes:** Accumulated cellular damage and reduced repair efficiency.

Cancer generally develops through multiple stages as cells acquire the ability to evade growth controls, resist apoptosis, escape immune surveillance and invade surrounding tissues.

Understanding these mechanisms helps guide cancer prevention, diagnosis and treatment. Depending on the cancer type and stage, treatment may include surgery, chemotherapy, radiation therapy, immunotherapy or targeted therapy. Supportive care, including nutrition, physical activity and psychological support, can also help maintain quality of life during treatment.

HOW REJWIN ADDRESSES THE HALLMARKS OF CANCER ?


Developed with high scientific rigour, **REJWIN** is formulated with a multi-targeted Phyto-complex designed to target key biological vulnerability pathways in tumour growth. **REJWIN** has been designed around the principle that cancer-associated biology is multifactorial. Its supportive concept is based on addressing several areas of physiological importance rather than claiming to act through one isolated pathway.

- **Oxidative-stress support:** Oxidative stress occurs when the production of reactive molecules exceeds the body's antioxidant defences. Excessive oxidative stress may contribute to cellular damage, inflammation and impaired physiological balance. Rejwin is intended to provide antioxidant support that may help the body manage oxidative challenges and protect normal cellular functions.
- **Inflammation-management support:** Persistent, uncontrolled inflammation may affect tissue health, immune signalling and metabolic balance. Rejwin's supportive approach includes ingredients selected for their traditional and scientifically investigated potential to support a balanced inflammatory response.
- **Immune-system support:** A healthy immune system plays an important role in surveillance, recovery and protection against internal and external stressors. Rejwin aims to support immune resilience and general host defence through nutritional and herbal support.
- **Cellular-protection support:** Cellular health depends on balanced antioxidant defences, adequate nutrition, normal metabolism, effective repair processes and appropriate elimination of damaged cells. Rejwin is positioned as a supportive formulation for maintaining these fundamental aspects of health.
- **Metabolic and nutritional support:** Cancer and its treatment may affect appetite, digestion, nutrient intake, energy levels and body weight. Rejwin is intended to support nutritional well-being and overall vitality as part of a comprehensive care plan.
- **Support for tissue and microenvironment balance:** The tissue environment around abnormal cells can influence inflammation, oxidative stress, immune activity and cellular communication. Rejwin's multi-component design is intended to support systemic balance rather than target only one aspect of this environment.

- **Recovery and quality-of-life support:** Cancer care may be physically and emotionally demanding. By supporting general vitality, digestive comfort, nutritional status and resilience, Rejwin may be used as part of an individualized supportive-care program.
- **Re-establishing Apoptosis (Programmed Cell Death):** Cancer cells evade apoptosis by downregulating pro-apoptotic effectors and overexpressing anti-apoptotic proteins.

Rejwin restores natural cell death through the intrinsic mitochondrial pathway:

- **Upregulation of Pro-Apoptotic Markers:** Increases expressions of p53, BAX, BAD, and DNA double-strand break marker.
- **Downregulation of Survival Signals:** Suppresses Bcl-xL (anti-apoptotic member).
- **Mitochondrial Permeabilization:** Triggers Cytochrome-C release into the cytosol, activating the caspase cascade (Caspase-3, 8, 9, 10) to initiate clean, non-inflammatory and cell clearance.
- **Anti-Angiogenesis (Starving the Tumour):** Without vascularization, microscopic tumours remain dormant due to lack of oxygen and nutrients. Rejwin inhibits tumour angiogenesis by targeting key growth factors and enzymes:
- **VEGF-A Suppression:** Significantly reduces Vascular Endothelial Growth Factor A (VEGF-A), cutting off signals for endothelial capillary sprouting.
- **MMP-2 & MMP-9 Downregulation:** Suppresses Matrix Metalloproteinases (MMP-2 and MMP-9), preventing extracellular matrix degradation and blocking endothelial and cancer cell invasion.
- **Cell Cycle Arrest & Anti-Proliferation:** Rejwin arrests the tumour cell cycle at the S-G2/M transition phase, halting DNA synthesis and preventing unchecked mitosis.



Noni based Herbal Formulation



Kanchanara



Haridra



Putranjeevaka



Lakshman Phal



Noni




Seemarouba




Kumuda




Active Principles of RJ




Salicylic acid




Genistein



Gallic acid




Luteolin




Chlorogenic acid




Curcumin




Emodin




Robinetin



Apigenin



Rutin



Quercetin

OBJECTIVE

To evaluate the In-vitro and In-vivo anticancer potential of **REJWIN** through cytotoxicity, anti-proliferative, apoptotic, anti-angiogenic and tumor inhibition studies.

TEST MATERIAL

REJWIN (Test Substance) was investigated as the test sample against selected cancer cell lines and normal cell lines, followed by animal studies for toxicity and tumor efficacy.

STUDY DESIGN

Study Component	Description
Cell-based Screening	Screening on multiple cancer and normal cell lines
Cytotoxicity Assay	MTT, Trypan blue and LDH assays
Proliferation Assay	IC_{50} determination and clonogenic assay
Apoptosis Assessment	FACS, Annexin V, DAPI, Hoechst, TUNEL, and immunoblot analysis
In-Vivo Toxicity	Non-tumor-bearing mice study
Antitumor Efficacy	Ascitic, Solid tumor, Lung adenocarcinoma model, Hepatocellular Carcinoma model and Xenograft models
Angiogenesis Study	Migration, invasion, CAM and Matrigel plug assays

MATERIALS AND METHODS


Method	Purpose
MTT assay	Assessment of cell viability and cytotoxicity
Trypan blue dye exclusion assay	Evaluation of live and dead cells
LDH leak assay	Assessment of membrane damage
IC_{50} determination	Determination of inhibitory concentration
Clonogenic assay	Assessment of long-term cell survival
FACS analysis	Analysis of apoptosis and cell cycle
Annexin V staining	Detection of early apoptosis
DAPI/Hoechst/Acridine orange staining	Detection of nuclear condensation and DNA damage
TUNEL assay	Detection of DNA fragmentation
Immunoblot analysis	Detection of apoptosis-related proteins
CAM and Matrigel plug assay	Evaluation of anti-angiogenic activity

CELL LINES EVALUATED

Sl. No.	Cell Line	Organism	Tissue	Type	IC50 Activity
1	A375	Human	Skin	Melanoma	13.2
2	B16F10	Mouse	Skin	Melanoma	11.2
3	HeLa	Human	Uterus/Cervix	Adenocarcinoma	8.2
4	A549	Human	Lung	Lung adenocarcinoma	8.5
5	MDA-MB-231	Human	Breast/ Mammary gland	Adenocarcinoma	8.9
6	MDA-MB-468	Human	Breast/ Mammary gland	Adenocarcinoma	9.8
7	MCF7	Human	Breast/ Mammary gland	Adenocarcinoma	9.1
8	CaCo2	Human	Large intestine /Colon	Colorectal adenocarcinoma	12.8
9	HCT15	Human	Large intestine /Colon	Colorectal carcinoma	11.3
10	HCT116	Human	Large intestine /Colon	Colorectal adenocarcinoma	12.9
11	HT29	Human	Large intestine /Colon	Colorectal adenocarcinoma	13.9
12	HepG2	Human	Liver	Hepatocellular carcinoma	8.4
13	PA01	Human	Ovary	Teratocarcinoma	9.8
14	U87	Human	Brain	Glioblastoma	15.1
15	Beas 2B	Human	Lung (Normal)	Lung epithelial cell	52.8
16	NIH3T3	Mouse	Embryo (Normal)	Fibroblast	45.0
17	Raw 264.7	Human	(Ascites Normal)	Macrophages	29.5
18	L132	Human	Lung (Normal)	Lung epithelial cell	56.0
19	HaCat	Human	Keratinocytes (Normal)	Fibroblast	65.0

APOPTOSIS AND CELL CYCLE FINDINGS


Observation	Result
Cell cycle arrest	S-G2/M phase arrest observed
Comet assay	DNA double-strand damage observed
DAPI staining	Nuclear condensation observed
Annexin V assay	Early and late apoptotic populations increased
TUNEL assay	DNA fragmentation confirmed
Protein/gene expression	Increased p53, BAX, BAD, and γH2AX; decreased Bcl-xl and cytochrome-c




Cell cycle arrest




Comet assay




DAPI staining



Annexin V assay




TUNEL assay




Protein/gene expression

ANTI - ANGIOGENIC ACTIVITY

Assay	Observation
Migration assay	Migration inhibited in a dose-dependent manner.
Invasion assay	Invasion suppressed.
VEGF-A expression	Reduced.
MMP-2 expression	Reduced.
MMP-9 expression	Reduced.
CAM/Matrigel plug assay	Reduced angiogenesis observed.





RESULTS SUMMARY


- **REJWIN** showed cytotoxic activity across multiple cancer cell lines, with comparatively higher IC_{50} values in normal cell lines, suggesting selective action toward tumor cells.
- **REJWIN** also demonstrated prolonged cytotoxicity, anti-clonogenic activity, apoptosis induction and cell cycle arrest at the S-G2/M phase.
- **REJWIN** reduced migration, invasion and expression of VEGF-A, MMP-2, and MMP-9, indicating anti-angiogenic activity.



IN VIVO EFFICACY STUDIES


ASCITIC TUMOR MODEL (EAC)

Model	Treatment	Major Observation
Ascitic tumor model (EAC)	**REJWIN** 25 and 50 mg/kg/b.w.	Reduced ascites volume, cell density and improved survivability.




SOLID TUMOR MODEL


Model	Treatment	Major Observation
Solid tumor model	**REJWIN** 25 and 50 mg/kg/b.w.	Reduced tumor size, mass, weight and improved survivability.



XENOGRAFT MODEL

Model	Treatment	Major Observation
Xenograft model	**REJWIN** 5 and 10 mg	Tumor regression observed.









LUNG ADENOCARCINOMA MODEL

Model	Treatment	Major Observation
Lung adenocarcinoma model	**REJWIN** 25 and 50 mg/kg/b.w.	Tumor hallmarks suppressed.



HEPATOCELLULAR CARCINOMA MODEL

Model	Treatment	Major Observation
Hepatocellular carcinoma model	**REJWIN** 25 and 50 mg/kg/b.w.	Tumor regression observed.




IN-VIVO TOXICITY STUDY

Parameter	Control	Rejwin	Observation
Body weight	Normal	Normal	No significant change.
Food consumption	Normal	Normal	No adverse effect.
Water intake	Normal	Normal	No adverse effect.
Hematology	Normal	Normal	No alteration.
SGOT/SGPT	Normal	Normal	Liver function maintained.
Creatinine/Urea	Normal	Normal	Renal function maintained.


Physiological effect of RJ on non tumour bearing mice

	Body weight (g)		Food Consumption (g)		Water intake (ml)	
	Control	RJ	Control	RJ	Control	RJ
0 Day	23.9±1.3	23.8±1.1	-	-	-	-
1st week	25.4±0.9	25.9±1.7	27.4±1.4	28.9±1.8	30.9±1.7	30.4±1.1
2nd week	27.4±1.4	27.7±1.3	57.9±1.5	60.1±0.9	64.3±1.4	67.1±1.3



HOSTOPATHOLOGY SUMMARY

Organ	Observation
Liver	No apparent alteration.
Lung	No apparent alteration.
Spleen	No apparent alteration.
Colon	No apparent alteration.
Kidney	No apparent alteration.
Intestine	No apparent alteration.
Brain	No apparent alteration.
Stomach	No apparent alteration.
Tongue	No apparent alteration.
Testis	No apparent alteration.



RESULT OF GROSS PATHOLOGICAL EXAMINATIONS

Model	Treatment	Major Observation
RA 01	2000 mg/kg	No macroscopic alteration occured
RA 02		No macroscopic alteration occured
RA 03		No macroscopic alteration occured
RA 04	Limit Test (2000 mg/kg)	No macroscopic alteration occured
RA 05		No macroscopic alteration occured
RA 06		No macroscopic alteration occured
RA 04		No macroscopic alteration occured
RA 05		No macroscopic alteration occured
RA 06		No macroscopic alteration occured

Figure 1: Body weight of animals at 2000mg/kg dose from Day 0 to Day 14




Figure 2: Body weight of animals at limit test dose 2000mg/kg dose from Day 0 to Day 14




Figure 3: Gross Pathological examination of treated animals (Macroscopic observation)




Figure-3a: Liver



Figure-3b: Kidney



Figure-3c: Spleen




Figure-3d: Heart



CONCLUSION

Based on the in-house evaluation, **REJWIN** demonstrated significant anticancer activity through cytotoxic, apoptotic, anti-proliferative and anti-angiogenic mechanisms, with no remarkable toxicity in the tested non-tumor-bearing animal model.



KEY BENEFITS OF REJWIN

REJWIN is intended to provide supportive benefits as part of an integrated care and wellness plan, complementing appropriate medical treatment and healthy lifestyle practices to promote overall well-being.

- **Antioxidant Support:** Supports the body's natural antioxidant defence system, helping maintain normal cellular protection against oxidative stress and associated cellular damage.
- **Immune Resilience:** Provides nutritional and herbal support intended to maintain normal immune function, strengthen physiological resilience and support the body's natural defence mechanisms.
- **Inflammation Balance:** Aims to support a healthy inflammatory response and maintain overall systemic balance, contributing to general health and well-being.
- **Cellular Wellness:** Helps support normal cellular health, metabolic balance and the body's natural protective mechanisms against everyday physiological stress.
- **Energy and Vitality:** Supports general strength, energy levels and day-to-day vitality as part of a balanced approach to nutrition, rest and healthy lifestyle practices.
- **Holistic Supportive Care:** Offers a multidimensional wellness approach that may be incorporated into a broader care plan involving medical treatment, balanced nutrition, regular physical activity, adequate sleep, psychological support and routine clinical monitoring.
- **Adjunctive Ayurvedic Support:** Explores the potential role of an Ayurvedic formulation in influencing biological pathways associated with tumour growth, tissue invasion and angiogenesis (the formation of new blood vessels).
- **Support During Cancer Treatment:** Aims to explore potential supportive benefits for quality of life during cancer treatment, including the management of treatment-related side effects.
- **Immune and Tissue Support:** Focuses on maintaining normal immune function, supporting systemic antioxidant defences and promoting general tissue health as part of a comprehensive supportive-care programme.

Rejwin

CORE BENIFITS

- **Inhibits Tumour Growth & Proliferation:** Suppresses unchecked cell division and induces targeted apoptosis in malignant cells.
- **Anti-Angiogenic Action:** Reduces pro-angiogenic factors (VEGF-A, MMP-2, MMP-9), helping to restrict the supply of blood and nutrients to tumour tissues.
- **Antioxidant & Free-Radical Scavenging:** Neutralizes reactive oxygen species (ROS) to protect healthy cells from oxidative stress and DNA damage.
- **Adjuvant Support:** Fits alongside standard oncology therapies (chemotherapy/radiation) to help manage side effects like fatigue, loss of appetite, and systemic weakness.
- **Non-Toxic to Healthy Tissues:** Pre-clinical studies demonstrate high selectivity for malignant cells without damaging healthy organ systems.

WHY A MULTI-TARGET APPROACH MATTERS ?

Cancer biology involves several overlapping mechanisms. A formulation that focuses only on antioxidant activity, only on immunity or only on inflammation may not adequately represent the complexity of the cancer-care environment.

REJWIN is based on a broader supportive framework:
Oxidative stress + inflammation + immune balance + nutrition + cellular wellness + vitality

These areas are interconnected. Oxidative stress may affect inflammatory signalling; inflammation may influence immune and metabolic function; poor nutrition may reduce resilience; and reduced vitality may affect recovery and quality of life. **REJWIN'S** intended value lies in bringing these supportive dimensions together in one formulation, while maintaining appropriate scientific, regulatory and clinical boundaries.

Rejwin

UNIQUE SELLING POINTS

- **Patented Herbal Formulation:** Backed by Indian Patent No. 591524. "A Method and Composition for Preparation of Herbal Solution for Cancer Treatment".
- **Scientifically & Pre-Clinically Validated:** Tested across 14 malignant cell lines and multiple In-vivo models.
- **Targeted Dual Action:** Combines pro-apoptotic activity (restoring natural cell death in malignant cells) with anti-angiogenic action (inhibiting new blood vessel growth towards malignant tumours).
- **High Safety & Selectivity Index:** Selective toward malignant cells with minimal toxicity to healthy tissues, as demonstrated in toxicology testing.
- **Quality Certifications:** Manufactured in perpetual AYUSH-licensed facilities License No. AUS-862, with GMP and ISO 9001:2015 quality certifications.
- **Complete Traceability:** Produced under a strictly controlled farm-to-product manufacturing model.
- **Multi-target supportive formulation: REJWIN** is designed to support several areas of wellness: including antioxidant defence, immune resilience, inflammation balance, cellular health, nutrition and vitality; rather than presenting a single-pathway concept.
- **Cancer-care support without replacement claims:** The product is positioned as an supplementary wellness formulation. It does not claim to replace oncology treatment, allowing the communication to remain responsible and patient-centred.
- **Science-informed product concept:** The formulation concept is aligned with contemporary understanding of cancer biology, including oxidative stress, inflammation, immune evasion, altered metabolism, cellular survival and the tumour microenvironment.
- **Holistic patient-support orientation: REJWIN** considers the person beyond the tumour by focusing on general strength, nutritional support, resilience, and quality of life.
- **Herbal and ayurvedic positioning:** The product combines the traditional relevance of herbal support with the structured approach of ayurvedic product development, quality evaluation, standardization and responsible communication.
- **Designed for integrated care: REJWIN** can be considered as part of a broader care strategy involving the treating oncologist, dietitian, pharmacist, Ayurvedic physician and other qualified healthcare professionals.

THE PRINCIPAL OBJECTIVES OF REJWIN

- Support the body's natural antioxidant defence mechanisms.
- Promote general cellular and metabolic wellness.
- Support healthy immune function.
- Help maintain balance in inflammatory responses.
- Complement nutritional and lifestyle support during the cancer-care journey.
- Support energy, vitality and improve quality of life.
- Offer patients and caregivers a clearly communicated product focused on wellness, resilience and supportive care.

WHO MAY CONSIDER REJWIN ?

REJWIN may be considered for adults seeking nutritional and herbal support during the cancer-care journey, subject to professional advice and individual suitability.
It may be relevant for:

- Individuals undergoing cancer treatment who require supportive nutritional planning.
- Individuals in recovery who wish to support general vitality.
- Individuals seeking antioxidant and immune-supportive wellness care.
- Caregivers looking for a structured supportive-care product.
- Health professionals developing an integrated wellness plan for suitable patients.

IMPORTANT SAFETY INFORMATION

- **REJWIN** is not a cure for cancer.
- It must not be used as a substitute for prescribed cancer treatment.
- Do not stop or modify chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, targeted therapy or other medicines without medical advice.
- Consult an oncologist or qualified healthcare professional before use, especially during active treatment, surgery, pregnancy, breastfeeding, liver or kidney disease or when multiple medicines are being taken.
- Report any unusual symptoms, allergy, gastrointestinal discomfort, bleeding tendency, or other adverse event to a healthcare professional.
- Nutritional requirements vary substantially between individuals. Patients should discuss the use of any supplement with their oncologist or clinical nutritionist, particularly during active treatment.
- The response to any supplement can differ from person to person. Benefits should be evaluated in consultation with a healthcare professional.
- **REJWIN** is a supportive Ayurvedic formulation and is not a substitute for oncology treatment. Always use it under the guidance of a qualified healthcare professional.
- Keep out of reach of children.
- Store as directed on the product label.
- Use only the recommended serving or dosage.

DISCLAIMER

REJWIN is an herbal and ayurvedic, supplement supportive-care product intended to support general wellness, antioxidant defence, immune function, nutritional status and vitality. It is not intended to diagnose, treat, cure or prevent cancer or any other disease. **REJWIN** is not a replacement for surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, hormonal therapy or any treatment prescribed by a qualified healthcare professional.

Cancer care is a journey that requires medical expertise, nutritional attention, emotional support and informed personal care. **REJWIN** has been developed with a multi-target supportive philosophy to help address important aspects of overall wellness; including antioxidant protection, immune resilience, inflammation balance, cellular health, nutrition and vitality. With responsible use, professional guidance, and continued medical supervision, **REJWIN** may form part of an integrated supportive-care approach focused on helping individuals maintain strength and well-being throughout their cancer-care journey.

MANUFACTURED BY

Live Long Live Strong

Valyou Products Private Limited

Ramenakoppa, Hosahalli Post,
Shivamogga - 577202.

www.valyouproducts.com

customercare@valyouproducts.com

MARKETED BY

Eesha HERBALS

Eesha Herbals

No 68, Banashree, Kolluraiah Street,
3rd Cross, Shivamogga - 577202

www.rejwin.com

eeshaherbals09@gmail.com

SHASHIKANTH NADIG

BBM, ACS

Proprietor, Eesha Herbals

9845380465

Customer Care

9108504009

9535581009